申请人:Takeda Pharmaceutical Company Limited
公开号:EP1593680A1
公开(公告)日:2005-11-09
The present invention provides a compound represented by the formula:
wherein R1 is a 5- or 6-membered ring which may be substituted;
R3 is a hydrogen atom, a lower alkyl group or a lower alkoxy group;
Z1 is a 5- or 6-membered aromatic ring;
Z2 is a group represented by -Z2a-W2-Z2b- wherein Z2a and Z2b are each O, S(O)m (wherein m is 0, 1 or 2), an imino group, or a bond; and W2 is an alkylene chain which may be substituted;
n is an integer of 0 to 4;
Y is O, S(O)p (wherein p is 0, 1 or 2), CH2 or NR4 (wherein R4 is a hydrogen atom, a hydrocarbon group, a heterocyclic group, or an acyl group); and
R2 is (1) an amino group , in which the nitrogen atom is converted to quaternary ammonium or oxide, (2) a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as a ring-constituting atom, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide, and the like, or a salt thereof.
The compound has excellent CCR5 antagonist activity and is useful as a prophylactic and/or therapeutic medicine for HIV infection in human peripheral mononuclear blood cells, especially AIDS.
本发明提供了一种由式表示的化合物:
其中 R1 是可被取代的 5 或 6 元环;
R3 是氢原子、低级烷基或低级烷氧基;
Z1 是 5 或 6 元芳香环;
Z2 是由 -Z2a-W2-Z2b- 代表的基团,其中 Z2a 和 Z2b 分别是 O、S(O)m(其中 m 是 0、1 或 2)、亚氨基或键;以及 W2 是可被取代的亚烷基链;
n 是 0 至 4 的整数;
Y 是 O、S(O)p(其中 p 是 0、1 或 2)、CH2 或 NR4(其中 R4 是氢原子、烃基、杂环基或酰基);以及
R2 是 (1) 氨基,其中氮原子转化为季铵或氧化物;(2) 含氮杂环基团,可包含一个硫原子或一个氧原子作为成环原子,其中氮原子可转化为季铵或氧化物等,或其盐。
该化合物具有优异的 CCR5 拮抗剂活性,可作为人类外周单核细胞感染 HIV(尤其是 AIDS)的预防和/或治疗药物。